1. Home
  2. DSGX vs DFTX Comparison

DSGX vs DFTX Comparison

Compare DSGX & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Descartes Systems Group Inc. (The)

DSGX

Descartes Systems Group Inc. (The)

SELL

Current Price

$95.35

Market Cap

6.6B

Sector

Technology

ML Signal

SELL

Logo Definium Therapeutics Inc. Common Shares

DFTX

Definium Therapeutics Inc. Common Shares

SELL

Current Price

$30.21

Market Cap

5.9B

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
DSGX
DFTX
Founded
1981
N/A
Country
Canada
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
6.6B
5.9B
IPO Year
1999
2020

Fundamental Metrics

Financial Performance
Metric
DSGX
DFTX
Price
$95.35
$30.21
Analyst Decision
Buy
Strong Buy
Analyst Count
14
19
Target Price
★ $102.62
$72.83
AVG Volume (30 Days)
383.3K
★ 1.5M
Earning Date
12-02-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.95
N/A
Revenue Next Year
$12.84
N/A
P/E Ratio
$37.05
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$62.56
$14.62
52 Week High
$96.75
$49.70

Technical Indicators

Market Signals
Indicator
DSGX
DFTX
Relative Strength Index (RSI) 64.17 37.55
Support Level $69.79 $20.43
Resistance Level $95.88 $38.59
Average True Range (ATR) 2.47 2.10
MACD -0.24 -0.21
Stochastic Oscillator 82.64 3.34

Price Performance

Historical Comparison
DSGX
DFTX

About DSGX Descartes Systems Group Inc. (The)

Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Share on Social Networks: